Analytical Data
-
基因名
FKTN
- Application
-
别名
FKTN；FCMD；Ribitol-5-phosphate transferase FKTN
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O75072
-
表达区间
1-461aa
-
氨基酸序列
MSRINKNVVLALLTLTSSAFLLFQLYYYKHYLSTKNGAGLSKSKGSRIGF DSTQWRAVKKFIMLTSNQNVPVFLIDPLILELINKNFEQVKNTSHGSTSQ CKFFCVPRDFTAFALQYHLWKNEEGWFRIAENMGFQCLKIESKDPRLDGI DSLSGTEIPLHYICKLATHAIHLVVFHERSGNYLWHGHLRLKEHIDRKFV PFRKLQFGRYPGAFDRPELQQVTVDGLEVLIPKDPMHFVEEVPHSRFIEC RYKEARAFFQQYLDDNTVEAVAFRKSAKELLQLAAKTLNKLGVPFWLSSG TCLGWYRQCNIIPYSKDVDLGIFIQDYKSDIILAFQDAGLPLKHKFGKVE DSLELSFQGKDDVKLDVFFFYEETDHMWNGGTQAKTGKKFKYLFPKFTLC WTEFVDMKVHVPCETLEYIEANYGKTWKIPVKTWDWKRSPPNVQPNGIWP ISEWDEVIQLY
-
分子量
57 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FKTN (Fukutin) is a critical protein involved in the post-translational modifications of glycoproteins, especially in the context of the muscular dystrophy known as Fukuyama congenital muscular dystrophy (FCMD). This rare genetic disorder is caused by mutations in the FKTN gene, leading to a deficiency in Fukutin and resulting in severe muscle weakness and developmental delays in affected individuals. Research on FKTN focuses on its essential role in the glycosylation process, specifically the formation of the glycosylated dystroglycan complex, which is crucial for maintaining the structural integrity of muscle fibers. Mutations in FKTN disrupt this process, contributing to the pathophysiology of FCMD and other related disorders. Understanding the functional dynamics of FKTN and its interactions within the glycosylation pathway presents significant potential for therapeutic strategies, including gene therapy and molecular interventions aimed at restoring normal protein function. Consequently, ongoing studies are dedicated to elucidating the molecular mechanisms governing FKTN's activity, the impact of specific mutations, and the broader implications for neuromuscular diseases, emphasizing its significance in both fundamental science and potential clinical applications.
